The following side effects are expected to occur with the use of sarecycline. Contact your doctor if these symptoms are severe and/or do not go away:
How Common (based on clinical studies)
| Nausea | Up to 4.6% of all users |
| Headache | Up to 2.8% of all users |
| Nasopharyngitis | Up to 2.8% of all users |
| Vomiting | Up to 2.1% of all users |
| Vaginal mycotic infection | Up to 0.8% of all users |
| Vaginal candidiasis | Up to 0.6% of all users |
| Dizziness | Less than 1% of all users |
| Photosensitivity | Less than 1% of all users |
| Abdominal discomfort | Unknown |
If you experience any of the following side effects, stop using sarecycline immediately and contact your doctor or get emergency medical care right away:
- Rash that occurs alongside fever and swollen glands in the neck or elsewhere
- Trouble breathing or swallowing
- Reappearance of sore throat, fever, and/or other symptoms of infection
- Swelling of the eyes, lips, tongue, throat, or face
- A sudden appearance of swelling and rash (known as hives)
- Chest pain
Sarecycline may also cause other side effects that are not mentioned here. Contact your doctor if you experience any other troublesome symptoms when using sarecycline.
References
- DailyMed (2023). Sarecycline. [online] Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b200957c-3004-4988-be97-9fd619a83649. [Accessed 08 Oct. 2023]
- Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S, Kempers SE, Kircik LH, Parish JL, Rendon MI, Rich P, Stein-Gold L, Tyring SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. Journal of Drugs in Dermatology. 17(9), 987-996 (2018).
- Leyden JJ, Sniukiene V, Berk DR, Kaoukhov A. Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study. Journal of Drugs in Dermatology. 17(3), 333-338 (2018).